Oncogenic mutations lead to constitutive activation of the BRAF/MEK/ERK (MAPK) signaling pathway, which plays a key role in the development and progression of melanoma by regulating a wide range of cellular processes, including proliferation, survival, invasion and metastasis, as well as by modulating immune responses [4,5,6]. Here, BRAF is linked to melanoma.